ZMYND10 Antibody

What is ZMYND10 and why is it important to study with antibody-based approaches?

ZMYND10 (Zinc Finger MYND Domain-Containing Protein 10) is a cytoplasmic protein that functions as a co-chaperone in the assembly of axonemal dynein motors required for cilia motility. It plays a critical role in conferring specificity for the FKBP8-HSP90 chaperone complex toward axonemal dynein clients . Mutations in ZMYND10 cause primary ciliary dyskinesia (PCD), characterized by recurrent respiratory infections and male infertility .

Antibody-based approaches are essential for studying ZMYND10 because:

• They allow detection of endogenous protein in tissue samples and cell cultures

• They enable visualization of subcellular localization through immunohistochemistry

• They facilitate protein interaction studies through co-immunoprecipitation experiments

• They help validate knockout or mutant models through western blotting

For optimal results, researchers should select antibodies validated for their specific application, considering factors such as species reactivity, epitope location, and clonality.

Which applications are validated for commercially available ZMYND10 antibodies?

Current ZMYND10 antibodies have been validated for several research applications, with varying degrees of optimization:

When selecting an antibody, researchers should review validation data for their specific application. For instance, rabbit polyclonal antibodies against ZMYND10 have been successfully used in co-immunoprecipitation experiments to pull down endogenous ZMYND10-containing complexes from mouse testes extracts .

What is the subcellular localization pattern expected when using ZMYND10 antibodies?

ZMYND10 predominantly localizes to the cytoplasm, with specific subcellular associations relevant to its function in dynein assembly . When using immunohistochemistry or immunofluorescence with ZMYND10 antibodies, researchers should expect:

• Strong cytoplasmic staining

• Association with the cytoskeleton and microtubule organizing centers

• Localization to centrosomes and centriolar satellites

• Presence in dynein axonemal particles

• Potential apical cell membrane association in ciliated epithelia

In spermatogenic cells, ZMYND10 shows high expression in the cytoplasm of round and elongating spermatids, as well as in maturing sperm . This localization pattern aligns with its functional role in cytoplasmic pre-assembly of axonemal dynein components prior to their transport to the ciliary/flagellar compartment.

How can I design experiments to investigate ZMYND10's role in the chaperone relay during axonemal dynein assembly?

To investigate ZMYND10's role in chaperone-mediated dynein assembly, consider these methodological approaches:

Protein interaction studies:

• Perform co-immunoprecipitation using ZMYND10 antibodies to pull down endogenous complexes from ciliated cell extracts or tissues with active ciliogenesis (e.g., testes extracts)

• Validate interactions with FKBP8 and HSP90 by immunoblotting precipitated samples

• Use label-free quantitative proteomics to identify all interacting partners

• Compare wild-type samples with those expressing disease-causing ZMYND10 variants

Functional assays:

• Test the effects of FKBP8 pharmacological inhibition and compare phenotypes with ZMYND10 mutant models

• Examine dynein motor stability in the presence/absence of ZMYND10

• Assess axonemal dynein heavy chain (HC) folding in ZMYND10 mutant vs. control samples

For quantitative analysis, label-free proteomics comparing postnatal testes extracts from control and Zmynd10 mutant mice has revealed that axonemal dynein heavy chains are significantly reduced, while other components like intermediate chains may remain initially unaffected . This suggests a primary role for ZMYND10 in heavy chain stability rather than in intermediate chain assembly.

What controls should be included when validating ZMYND10 antibody specificity?

Rigorous antibody validation is essential for reliable ZMYND10 detection. Include these critical controls:

Positive controls:

• Tissues with known high ZMYND10 expression (testes, respiratory epithelium)

• Cell lines transfected with ZMYND10 expression constructs

• Recombinant ZMYND10 protein (matching the immunogen used to generate the antibody)

Negative controls:

• ZMYND10 knockout tissues or cells (if available)

• Tissues known to express minimal ZMYND10

• Immunodepletion with recombinant ZMYND10 protein

• Pre-incubation of antibody with immunizing peptide before application

Validation strategies:

• Compare results from multiple antibodies targeting different ZMYND10 epitopes

• Verify band molecular weight (approximately 50 kDa) in western blots

• For immunoprecipitation validation, pull down with two different validated ZMYND10 antibodies (e.g., Sigma HPA035255 and Proteintech 14431-1-AP) as done in published research

• If possible, confirm specificity using orthogonal methods (e.g., mass spectrometry of immunoprecipitated proteins)

How can ZMYND10 antibodies be used to investigate the molecular pathogenesis of Primary Ciliary Dyskinesia (PCD)?

ZMYND10 antibodies provide valuable tools for studying PCD pathogenesis at molecular and cellular levels:

Patient sample analysis:

• Use immunohistochemistry on respiratory epithelial biopsies to assess ZMYND10 expression and localization in patients with suspected PCD

• Compare dynein arm component expression in control vs. PCD patient samples using co-staining approaches

• Evaluate ZMYND10 antibody staining patterns in relation to ciliary ultrastructural defects identified by TEM

Molecular mechanisms:

• Use co-immunoprecipitation to test whether disease-causing ZMYND10 variants disrupt interactions with FKBP8-HSP90

• Investigate whether mutant ZMYND10 retains its cytoplasmic localization or shows aberrant distribution

• Assess chaperone activity by examining dynein heavy chain stability in patient-derived cells

Model systems:

• Compare ZMYND10 antibody staining patterns in wild-type and mutant mouse models

• Use quantitative proteomics to profile dynein component stability in PCD models

• Investigate whether ZMYND10 loss affects other dynein assembly factors (DNAAFs)

Research has shown that loss of ZMYND10 triggers broader degradation of dynein motor subunits, suggesting PCD caused by mutations in dynein assembly factors should be considered a cell-type specific protein-misfolding disease .

What are the best methods for using ZMYND10 antibodies in protein interaction studies?

To effectively use ZMYND10 antibodies for studying protein interactions:

Co-immunoprecipitation protocol optimization:

• Lyse cells/tissues in buffers that preserve native protein complexes (avoid harsh detergents)

• Use magnetic beads coupled to protein A/G for antibody immobilization

• Pre-clear lysates to reduce non-specific binding

• Incubate with ZMYND10 antibody at 4°C overnight with gentle rotation

• Include appropriate negative controls (IgG from same species, non-expressing tissues)

Proximity ligation assays:

• Use ZMYND10 antibodies in combination with antibodies against suspected interaction partners

• Select antibodies raised in different species to enable co-detection

• Validate antibody specificity before proceeding with PLA

Analyzing chaperone interactions:

• When investigating ZMYND10 interactions with the FKBP8-HSP90 chaperone complex, consider using antibodies against HSP90 (e.g., Santa Cruz sc-13119) and FKBP8 (e.g., Proteintech 11173-1-AP) as used in published research

• For dynein intermediate chains, consider antibodies against DNAI1 (e.g., Abcam ab171964) and DNAI2 (e.g., Abnova H00064446-M01)

In published studies, endogenous ZMYND10-containing complexes have been successfully immunoprecipitated from mouse testes extracts at postnatal day 30, a period of synchronized flagellogenesis .

What are common problems when using ZMYND10 antibodies and how can they be resolved?

When working with ZMYND10 antibodies, researchers may encounter several challenges:

High background:

• Increase blocking time/concentration (use 5% BSA or normal serum)

• Reduce primary antibody concentration

• Increase washing steps (duration and number)

• For IHC, try antigen retrieval optimization

• Consider using more specific monoclonal antibodies if available

Weak or no signal:

• Verify ZMYND10 expression in your sample type

• Try different epitope-targeting antibodies (N-terminal vs. C-terminal)

• Optimize antibody concentration (try 1:30-1:150 for IHC)

• Test different detection systems

• For western blotting, ensure sample preparation preserves protein integrity

Multiple bands in western blot:

• Verify lysate preparation methods (presence of proteases)

• Check for post-translational modifications or splice variants

• Consider antibody cross-reactivity with related proteins

• Use more stringent washing conditions

Inconsistent immunoprecipitation:

• Test different lysis buffers to preserve interactions

• Optimize antibody:bead ratios

• Consider using antibodies validated specifically for IP applications

• Pre-clear lysates thoroughly to reduce non-specific binding

How can ZMYND10 antibodies be used to quantitatively assess protein expression in different experimental conditions?

For quantitative assessment of ZMYND10 expression:

Western blot quantification:

• Use loading controls appropriate for your experimental system (β-actin, GAPDH, etc.)

• Include a standard curve with recombinant ZMYND10 if absolute quantification is needed

• Analyze band intensity using densitometry software

• Normalize ZMYND10 signal to loading control

Immunofluorescence quantification:

• Use consistent image acquisition parameters

• Measure mean fluorescence intensity in defined cellular regions

• Include internal controls in the same image field

• Apply appropriate background subtraction methods

Comparative proteomics approach:

• For comprehensive analysis of ZMYND10 and related proteins, consider label-free quantitative proteomics

• Compare wild-type and mutant/knockout samples

• This approach can reveal broader changes in dynein assembly components

• Data can be analyzed for statistical significance as demonstrated in previous studies

Previous proteomics analysis comparing postnatal testes extracts from control and Zmynd10 mutant mice showed significant reduction of almost all axonemal dynein heavy chains while other axonemal components remained largely unchanged .